TGF-β signaling is known to influence the bioenergetic dynamics within cancer cells (glycolysis, oxphos, and lipid metabolism) [70] and plays a role in PI3K activation (via TGF-β and HER2 interactions), contributing to trastuzumab resistance [71]. Here, ERBB2 is linked to cancer.